Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amcor PLC (AMCR) vs ARK Genomic Revolution ETF (ARKG) Price & Performance

ARK Genomic Revolution ETFTrade

Price performance (Past 24H)

Key statistics

Amcor PLC vs ARK Genomic Revolution ETF — how do they compare? Amcor PLC trades at $46.58 (market cap $21.92B), while ARK Genomic Revolution ETF trades at $44.61. The key difference: Amcor PLC pays a 5.49% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Amcor PLC nearer its low. Which is the better fit depends on your goals.

AMCRARKG
Market Cap
$21.92B
Sector
Basic MaterialsSector/Thematic
52-Week High
$50.58$44.55
52-Week Low
$36.69$24.02
Enterprise Value
$37.03B
Dividend Yield
5.49%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amcor PLC

AMCR trades at $47.24, up 0.28% today, near the analyst consensus price target of $47.00. The stock exhibits a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $1.23, beating estimates, with revenue growth driven by the Berry acquisition. Net income margin stands at 3.06%, while the P/E ratio of 38.07 indicates a premium valuation. Recent news highlights strong Q4 earnings and expansion in China.

The outlook for AMCR is cautiously optimistic, supported by consistent earnings beats and strategic expansions. However, elevated valuation metrics and a high RSI pose near-term risks. Investor sentiment is positive with a 64% analyst buy rating, but margin pressures and integration risks from acquisitions warrant monitoring. The stock presents a balanced opportunity with growth catalysts tempered by valuation concerns.

ARK Genomic Revolution ETF

ARKG trades at $44.69 with a 0.86% daily gain, showing bullish momentum with strong moving average signals but overbought oscillators. The ETF focuses on genomic revolution companies with 59% concentration in top 10 holdings and long-term EPS growth of 10.7%. Recent news highlights biotech sector strength and ARKG's recovery from July correction.

Outlook remains positive given biotech sector tailwinds including FDA friendliness and AI-driven drug discovery, though high RSI readings suggest near-term caution. Key risks include sector volatility and concentrated portfolio exposure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amcor PLC

Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.

Read more on AMCR

About ARK Genomic Revolution ETF

ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.

Read more on ARKG